Investigating a new approach to target HIV-1 Nef for better treatment options
Chemical Biology of HIV-1 Nef
This study is looking at a part of the HIV virus called the Nef protein and testing new small molecules that can help the immune system better fight off HIV, which could lead to better treatments for people living with the virus.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-11013977 on NIH RePORTER |
What this research studies
This research focuses on the HIV-1 Nef protein, which plays a crucial role in the virus's ability to replicate and evade the immune system. The team has discovered small molecules that can bind to Nef and inhibit its function, potentially allowing the immune system to better recognize and eliminate HIV-infected cells. By developing innovative Proteolysis Targeting Chimeras (PROTACs), the research aims to promote the degradation of the Nef protein, thereby enhancing antiviral immunity and reducing viral reservoirs in patients. This approach could lead to more effective treatments for individuals living with HIV.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV who are currently on antiretroviral therapy and may benefit from new treatment options.
Not a fit: Patients who are not infected with HIV or those who have advanced AIDS with significant immune system damage may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that help eradicate HIV from infected individuals, reducing the need for lifelong antiretroviral therapy.
How similar studies have performed: Previous research has shown promise in targeting HIV-1 Nef, but this specific approach using PROTACs is relatively novel and has not been extensively tested.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Smithgall, Thomas E. — University of Pittsburgh at Pittsburgh
- Study coordinator: Smithgall, Thomas E.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.